Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rutherford

Showing results (521-530 of 603) with videos related to

Pageof 61
Sort By:
Neurology|April 29, 2014
Progranulin protein levels are differently regulated in plasma and CSFAlexandra M Nicholson, NiCole A Finch, Colleen S Thomas, et al.
European Journal of Gynaecological Oncology|May 14, 2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcomaM M Abu-Khalaf, M A Raza, C Hatzis, et al.
Neurology|April 19, 2013
Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosisAshley Cannon, Shinsuke Fujioka, Nicola J Rutherford, et al.
Gynecologic Oncology|March 31, 2015
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Katherine Bell-McGuinn, et al.
Cancer|April 16, 2013
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilonesDana M Roque, Stefania Bellone, Diana P English, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 14, 2012
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomasFederica Guzzo, Stefania Bellone, Natalia Buza, et al.
Cancer|June 22, 2011
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxinFrancesca Casagrande, Emiliano Cocco, Stefania Bellone, et al.
Human Pathology|March 9, 2018
MicroRNA signatures discriminate between uterine and ovarian serous carcinomasPei Hui, Stefan M Gysler, Mohamed Uduman, et al.
British Journal of Cancer|April 26, 2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyS Bellone, D Roque, E Cocco, et al.
Immunology and Cell Biology|December 15, 2000
HIV-1-specific cellular immune responses among HIV-1-resistant sex workersK R Fowke, R Kaul, K L Rosenthal, et al.
Pageof 61

Showing results (521-530 of 603) with videos related to

Sort By:
Pageof 61
Neurology|April 29, 2014
Progranulin protein levels are differently regulated in plasma and CSFAlexandra M Nicholson, NiCole A Finch, Colleen S Thomas, et al.
European Journal of Gynaecological Oncology|May 14, 2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcomaM M Abu-Khalaf, M A Raza, C Hatzis, et al.
Neurology|April 19, 2013
Clinicopathologic variability of the GRN A9D mutation, including amyotrophic lateral sclerosisAshley Cannon, Shinsuke Fujioka, Nicola J Rutherford, et al.
Gynecologic Oncology|March 31, 2015
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Katherine Bell-McGuinn, et al.
Cancer|April 16, 2013
Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilonesDana M Roque, Stefania Bellone, Diana P English, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 14, 2012
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomasFederica Guzzo, Stefania Bellone, Natalia Buza, et al.
Cancer|June 22, 2011
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxinFrancesca Casagrande, Emiliano Cocco, Stefania Bellone, et al.
Human Pathology|March 9, 2018
MicroRNA signatures discriminate between uterine and ovarian serous carcinomasPei Hui, Stefan M Gysler, Mohamed Uduman, et al.
British Journal of Cancer|April 26, 2012
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapyS Bellone, D Roque, E Cocco, et al.
Immunology and Cell Biology|December 15, 2000
HIV-1-specific cellular immune responses among HIV-1-resistant sex workersK R Fowke, R Kaul, K L Rosenthal, et al.
Pageof 61